FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
BLA FilingapprovedLeqembi IqlikPositive
AI Analysis
Summary
FDA approves Eisai's Leqembi Iqlik (lecanemab-irmb) subcutaneous injection for early Alzheimer's disease, expanding the therapeutic option for patients with a weekly dosing formulation. BioArctic AB partners with Eisai on this supplemental biologics license application approval.
Outcome Details
FDA approved supplemental Biologics License Application (sBLA) for once weekly lecanemab-irmb subcutaneous injection as a starting dose for early Alzheimer's disease
Importance:9/10
Sentiment:
0.95
FDA approvalBiologics License ApplicationSubcutaneous injectionAlzheimer's diseaseLecanemab
Related Companies
Read the original article
Published by PR Newswire Biotech on July 14, 2026 2:37 AM